Journals / Türk Kardiyoloji Derneği Arşivi / 2019 / Cilt: 47 - Sayı: 7

Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI

Mukopolisakkaridoz tip VI’lı çocuklarda kardiyovasküler bulgular ve enzim replasman tedavisinin etkisi

Pages
587–593
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

An echocardiographic examination should be performed periodically even if the patient has no clinical signs of cardiac disease, and any cardiac involvement should be kept under control with medical treatment

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The mucopolysaccharidoses (MPS) are an important group of lysosomal storage diseases.
📊
Key Findings & Data:The aim of this study was to evaluate cardiac involvement in patients with MPS type VI.Methods: The study included a total of 13 children with MPS type VI who were admitted to a single pediatric department between 2016 and 2018.
💡
Conclusion & Impact:An echocardiographic examination should be performed periodically even if the patient has no clinical signs of cardiac disease, and any cardiac involvement should be kept under control with medical treatment
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The mucopolysaccharidoses (MPS) are an important group of lysosomal storage diseases. Commonly reported cardiac involvement includes mitral leaflet thickening and accompanying prolapsus, regurgitation, and rarely, stenosis. The aim of this study was to evaluate cardiac involvement in patients with MPS type VI.Methods: The study included a total of 13 children with MPS type VI who were admitted to a single pediatric department between 2016 and 2018. Cardiac status was evaluated prospectively with clinical findings, electrocardiography, and echocardiography. The age of the patients (8 boys, 5 girls) ranged between 2 and 14 years (median: 9 years).Results: No arrhythmia was observed in any patient. Thickening of the mitral valve with or without regurgitation and prolapsus was the most common lesion seen. Additional involvement of the aortic valve was detected in 12 (92.3%) patients, and additional involvement of the tricuspid valve in 4 (30.8%). Isolated septal hypertrophy was found in 2 patients, and congestive heart failure in another.Conclusion: Cardiac involvement is frequent in MPS. Mitral valve deformation is the most frequent finding. An echocardiographic examination should be performed periodically even if the patient has no clinical signs of cardiac disease, and any cardiac involvement should be kept under control with medical treatment

Özet

Amaç: Mukopolisakkaridozlar (MPS) önemli bir lizozomal depo hastalığı grubu olup, kardiyovasküler sistemde en sık kalp kapakçıkları ve koroner arterlerde tutulum ile kendilerini gösterirler. Bu çalışmada, MPS tip VI tanısıyla izlenençocuklarda kardiyak tutulumun değerlendirilmesi amaçlanmıştır.Yöntemler: Mukopolisakkaridoz tip VI tanısı ile 2016−2018 yılları arasında izlenen 13 olgunun fizik muayene, elektrokardiyografi ve standart transtorasik ekokardiyografi bulguları geriye dönük olarak değerlendirildi. Hastaların (8 erkek, 5 kız) yaş aralığı 2–17 yaş (medyan 9) idi.Bulgular: Hastaların EKG’lerinde ritim bozukluğu ve iskemibulgusu saptanmadı. Ekokardiyografide mitral kapakta yetersizliği en sık görülen bulgu idi. Olguların 12’sine (%92.3) aort kapak yetersizliği, dördüne (%30.8) triküspit kapakyetersizliği eşlik ediyordu. İzole septal hipertrofi iki olguda mevcut idi. Bir olguda kapak tutulumuna ek sol ventrikül sistolik fonksiyonlarında bozulma görüldü.Sonuç: Mukopolisakkaridozda kardiyak tutulum herhangi bir zamanda ortaya çıkabilir. Mitral kapak deformasyonu en sık görülen bulgudur. MPS’li olgularda belirgin yakınmave fizik muayene bulgusu olmasa dahi, ekokardiyografik incelemede kardiyak tutulum saptanmaktadır. Bu nedenle olguların kardiyovasküler değerlendirmeleri düzenli olarakyapılmalıdır.

🔖

Cite This Article

AZAK, E., GÜNDÜZ, M. (2022). Cardiovascular findings and effects of enzyme replacement therapy in patients with mucopolysaccharidosis type VI. Türk Kardiyoloji Derneği Arşivi, Cilt: 47 - Sayı: 7, 587–593. https://ajindex.com/articles/632438

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics 2007;120:405–18
  2. Kampmann C, Lampe C, Whybra-Trümpler C, Wiethoff CM, Mengel E, Arash L, et al. Mucopolysaccharidosis VI: cardiac involvement and the impact of enzyme replacement therapy. J Inherit Metab Dis 2014;37:269–76
  3. Brands M, Roelants J, de Krijger R, Bogers A, Reuser A, van der Ploeg A, et al. Macrophage involvement in mitral valve pathology in mucopolysaccharidosis type VI (MaroteauxLamy syndrome). Am J Med Genet A 2013;161A:2550–3
  4. Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, et al. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 2011;34:1183–97
  5. Leal GN, de Paula AC, Leone C, Kim CA. Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 2010;20:254–61
  6. Dangel JH. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders-clinical and echocardiographic findings in 64 patients. Eur J Pediatr 1998;157:534–8
  7. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al; American Society of Echocardiography. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004;17:1086–119.8. Kampmann C, Wiethoff CM, Wenzel A, Stolz G, Betancor M, Wippermann CF, et al. Normal values of M mode echocardiographic measurements of more than 2000 healthy infants and children in central Europe. Heart 2000;83:667–72
  8. Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, et al; MPS VI Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy. J Inherit Metab Dis 2013;36:385–94
  9. Mohan UR, Hay AA, Cleary MA, Wraith JE, Patel RG. Cardiovascular changes in children with mucopolysaccharide disorders. Acta Paediatr 2002;91:799–804
  10. Fesslová V, Corti P, Sersale G, Rovelli A, Russo P, Mannarino S, et al. The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses. Cardiol Young 2009;19:170–8
  11. Rigante D, Segni G. Cardiac structural involvement in mucopolysaccharidoses. Cardiology 2002;98:18–20
  12. Nelson J, Shields MD, Mulholland HC. Cardiovascular studies in the mucopolysaccharidoses. J Med Genet 1990;27:94–100
  13. Brands MM, Oussoren E, Ruijter GJ, Vollebregt AA, van den H